when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

petrelintide · news · pharmadog

← back to petrelintide

News mentioning petrelintide

14 stories

3d3 takeaways from a European obesity scientific meetingbiopharma dive

5dLilly raises diabetes weight-loss bar with amylin-Zepbound combofiercebiotech

5dRoche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal programfiercebiotech

5dRoche cuts muscle-sparing obesity drug after mid-stage disappointmentbiospace

12dRoche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trialbiospace

Aug 28, 26Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical datafiercebiotech

Aug 27, 26Myriad catalysts on deck for obesity’s brightest stars as market continues to acceleratebiospace

Aug 24, 26Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drugbiospace

Aug 24, 26Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismfiercebiotech

Aug 13, 26Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionfiercebiotech

Jul 24, 26Roche cans one Carmot obesity asset as another shows best-in-class potentialbiospace

Jul 23, 26Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onbiospace

Jun 6, 26#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearendpoints

Apr 23, 26Roche, facing biosimilar threats, puts faith in new cancer and obesity drugsbiopharma dive